<DOC>
	<DOCNO>NCT00286091</DOCNO>
	<brief_summary>The purpose study compare treatment effect denosumab placebo prolong bone metastasis-free survival men hormone refractory ( androgen independent ) prostate cancer bone metastasis baseline .</brief_summary>
	<brief_title>Study Prolonging Bone Metastasis-Free Survival Men With Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description>Participants randomize receive denosumab 120 mg placebo every 4 week ( Q4W ) approximately 660 participant develop bone metastasis die primary efficacy safety analysis complete . All participant undergo scheduled assessment offer open-label denosumab 120 mg subcutaneous ( SC ) either develop bone metastasis , obtain access commercially available product setting , 3 year , whichever come first . For participant end participation open-label extension ( OLE ) phase withdraw investigational product OLE phase , survival data collect every 6 month 3 year last dose investigational product . Participants Czech Republic United Kingdom enrol separate protocol OLE phase per Health Authority request , report separately ( Study 20080585 ; NCT01824342 ) .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>men histologically confirm prostate cancer bilateral orchiectomy least 6 month randomization continuous androgendeprivation therapy ( ADT ) gonadotropin release hormone ( GnRH ) agonist antagonist least 6 month randomization total testosterone level le 50 ng/dL , hormone refractory ( androgen independent ) prostate cancer demonstrate continuous ADT/postorchiectomy define : 3 consecutive prostatespecific antigen ( PSA ) value PSA1 &lt; PSA2 &lt; PSA3 , PSA value must separate least 2 week , PSA2 PSA3 great equal 1.0 ng/mL , high risk development bone metastasis define PSA value great equal 8.0 ng/mL , obtain 3 month randomization OR PSA double time le equal 10.0 month prior current evidence radiographically detectable bone metastasis know prior current evidence metastatic involvement distant organ ( lymph node metastasis region acceptable ) prior current intravenous bisphosphonate administration</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Hormone refractory prostate cancer</keyword>
	<keyword>androgen independent</keyword>
	<keyword>ADT</keyword>
	<keyword>bone metastasis</keyword>
</DOC>